Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) and Kura Oncology (NASDAQ:KURA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
Analyst Ratings
This is a summary of current ratings and recommmendations for Sagimet Biosciences and Kura Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sagimet Biosciences | 2 | 0 | 9 | 0 | 2.64 |
| Kura Oncology | 1 | 1 | 11 | 0 | 2.77 |
Sagimet Biosciences currently has a consensus price target of $26.07, indicating a potential upside of 155.10%. Kura Oncology has a consensus price target of $25.88, indicating a potential upside of 233.11%. Given Kura Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe Kura Oncology is more favorable than Sagimet Biosciences.
Insider and Institutional Ownership
87.9% of Sagimet Biosciences shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Sagimet Biosciences and Kura Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sagimet Biosciences | N/A | -29.95% | -27.71% |
| Kura Oncology | -369.26% | -336.24% | -46.03% |
Risk & Volatility
Sagimet Biosciences has a beta of 3.43, meaning that its share price is 243% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
Earnings & Valuation
This table compares Sagimet Biosciences and Kura Oncology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sagimet Biosciences | $2.00 million | 317.64 | -$51.04 million | ($1.19) | -8.59 |
| Kura Oncology | $67.48 million | 10.58 | -$278.67 million | ($3.30) | -2.35 |
Sagimet Biosciences has higher earnings, but lower revenue than Kura Oncology. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Sagimet Biosciences beats Kura Oncology on 9 of the 13 factors compared between the two stocks.
About Sagimet Biosciences
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.
About Kura Oncology
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
